Mylan

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANI Pharma

Lannett Company

Pfizer

Taro Pharmaceutical Industries

Teva Pharmaceutical

Here's why a new initiative by the FDA to reduce drug prices is great for patients but should raise the alarm among pharmaceutical investors.

Why the FDA's Drug Competition Action Plan Is Bad News for Generic Pharmaceutical Stocks

HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lantus®...

Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings

Allstate

Cadence Design Systems

Progressive

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

Markets Set Out on Long Journey to Recovery: 4 ROE Picks

Gilead Sciences

Mylan will distribute the drug as a COVID-19 treatment in 127 low- and middle-income countries.

Gilead Strikes Deal With Mylan to Supply Remdesivir Internationally

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Mylan (MYL) Stock Undervalued Right Now?

Mylan N.V. (MYL) CEO Heather M. Bresch on Q1 2020 Results - Earnings Call Transcript

Some countries may have more domestic manufacturing than the U.S., but "no country's capable of.

Mylan CEO says its global supply chain helped it experience 'minimal disruption' during pandemic

Mylan (MYL) earnings for the pharmaceutical company's first quarter of 2020 have MYL stock falling on Monday after missing estimates.
The post Mylan Earnings: 5 Things for MYL Stock Investors to Know About Q1 appeared first on InvestorPlace.

Mylan Earnings: 5 Things for MYL Stock Investors to Know About Q1

The COVID-19 pandemic helped the drugmaker's sales more than it hurt.

What's Behind Mylan's Mixed Q1 Results

Mylan (MYL) beats on Q1 earnings but misses on sales.

Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling

Mylan (MYL) delivered earnings and revenue surprises of 2.27% and -2.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) Q1 Earnings Top Estimates

Mylan reported $2.62 billion in first-quarter sales on Monday, just below expectations. But MYL stock advanced in early trading.

Generic Pharma Giant Mylan Lags First-Quarter Sales Estimates

Shares of Mylan MYL, +1.44% gained 0.1% in premarket trading on Monday after the drugmaker reaffirmed its revenue guidance for the year.

Mylan's stock gains 2%; guidance for 2020 reaffirmed

Spoiler alert: The impact of Pfizer's coming dividend cut shouldn't be too painful.

How Low Will Pfizer's Dividend Go After the Mylan-Upjohn Deal?

Applied Materials

Cisco Systems

Under Armour

Duke Energy

Norwegian Cruise Line

Although earnings and other fundamentals are taking a backseat in the markets right now, they will be an important measure when the current crisis ends.

Applied Materials, Cisco, Mylan, Under Armour and More Earnings Due This Week

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Mylan (MYL) This Earnings Season?

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q1 results.

Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards?

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Mylan (MYL) is Poised to Beat Earnings Estimates Again

Mylan NV  on Wednesday named Chairman Robert Coury to the role of executive chairman to help steer the drugmaker through the coronavirus pandemic and its delayed merger with Pfizer Inc's  off-patent branded drug unit, Upjohn.

Mylan's Robert Coury back as executive chairman

Generic drugmaker Mylan NV  has offered concessions to address European Union antitrust concerns about its bid for Pfizer's  off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday.

Mylan offers concessions to address EU concerns about Pfizer deal

Mylan (MYL) reported earnings 30 days ago. What's next for the stock?

Mylan (MYL) Down 20.3% Since Last Earnings Report: Can It Rebound?

Amgen

Bristol-Myers

Eli Lilly

Merck

Several pharma & biotech companies announce their plan to fight coronavirus pandemic and state anticipated unfavorable impact of the outbreak on their business.

Pharma, Biotech Players Step Up Efforts Against Coronavirus

Inovio Pharmaceuticals

Moderna

Novartis

Regeneron Pharmaceuticals

Sanofi

An old malaria drug may unseat newer investigational coronavirus treatments -- if data is confirmed.

3 Things to Know if Chloroquine Wins the COVID-19 Treatment Race

Pfizer's plan to merge its post-exclusivity segment with Mylan will have to wait.

Coronavirus Pandemic Puts Upjohn-Mylan Megamerger on Hold

Biogen

Roche Holding AG

Vir Biotechnology

Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.

News for Mylan Stock (MYL)